Welcome to our dedicated page for Algernon Health news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on Algernon Health stock.
Algernon Health Inc. (AGNPF), formerly Algernon Pharmaceuticals Inc., generates news that reflects its transition from a purely clinical-stage pharmaceutical developer to a healthcare company focused on brain-specific PET neuroimaging clinics and neurological programs. Company announcements highlight its plans to build a network of specialized clinics in North America for the early-stage detection of Alzheimer’s disease and other brain disorders, as well as updates on its drug development and subsidiary activities.
Investors and observers following AGNPF news will see disclosures about neuroimaging initiatives, including equipment orders and financing agreements for U.S. FDA-cleared brain PET systems, partnerships with imaging technology providers, and franchise and licensing arrangements obtained through the acquisition of NoBrainer Imaging Centers, Inc. These items outline how Algernon intends to deploy dedicated clinics and expand access to brain PET imaging in selected Canadian and U.S. markets.
News releases also cover Algernon’s ongoing pharmaceutical and neuroscience programs. This includes updates from Algernon NeuroScience, the company’s private subsidiary advancing a proprietary DMT program for stroke and traumatic brain injury, as well as intellectual property milestones for its chronic kidney disease candidate NP-251 (Repirinast). Additional coverage may address capital markets activity such as private placements, preferred share structures, and regulatory steps related to planned financings.
For readers tracking AGNPF, the news stream provides context on how Algernon is combining diagnostic imaging, clinic development, and drug research. Regularly reviewing these updates can help users understand changes in the company’s strategic focus, progress on clinic rollouts, developments in its neurological pipeline, and the evolution of its capital structure.
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has filed a pre-IND meeting request with the U.S. FDA for its NP-120 (Ifenprodil) aimed at treating refractory chronic cough. This potential first-in-class treatment shows promising trends from an interim analysis of its ongoing Phase 2 study in Australia and New Zealand. Results revealed a significant reduction in cough counts after 12 weeks. Depending on FDA feedback, the U.S. Phase 2 study could begin in Q2 2022. Chronic cough, affecting 10% of adults, currently has no approved therapies.
Algernon Pharmaceuticals has filed a pre-IND meeting request with the U.S. FDA for its clinical program investigating NP-120 (Ifenprodil) for the treatment of small cell lung cancer (SCLC). This marks a significant step in the development of Ifenprodil, which shows promise when combined with Topotecan to inhibit tumor growth. SCLC accounts for 15% of lung cancers, with limited treatment options available for patients suffering from this condition. CEO Christopher J. Moreau expressed optimism about advancing the SCLC program rapidly, emphasizing the urgent need for new treatment avenues.
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announces the appointment of Dr. Mark Williams to its Board of Directors, succeeding Michael Sadhra, who resigned to pursue other ventures. Dr. Williams, a co-founder of the company's drug repurposing program, has over 15 years of experience in drug development. He holds a PhD in Microbiology and an MBA. CEO Christopher J. Moreau welcomes his extensive knowledge in pre-clinical and clinical development, enhancing the board's expertise.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) has announced plans to file a pre-IND meeting request with the FDA for a Phase 2 chronic cough study using NP-120 (Ifenprodil). The decision to expand the Ifenprodil research stems from positive interim data from a Phase 2 trial on idiopathic pulmonary fibrosis (IPF) and chronic cough. Preliminary results indicated a relative reduction in cough counts in patients, and the new study aims to focus solely on chronic cough, powered for statistical significance, with a placebo control.
Algernon Pharmaceuticals announced that CEO Christopher J. Moreau will give a keynote presentation at the Microdose Virtual 2021 DMT Conference on September 9th. Moreau's talk, titled “DMT – New Hope for Healing the Brain After a Stroke,” will present Algernon's unique clinical research program focused on DMT for stroke treatment. The preliminary study revealed that DMT increased the growth of cortical neurons by 40% at sub-hallucinogenic doses. Algernon aims to be the first to test DMT for stroke in humans, and has filed new provisional patents related to its treatment.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced the appointment of Harry Bloomfield, QC, as a new Board member and Chairman. Bloomfield brings significant experience as a lawyer and business manager, with a history in senior business roles and board memberships across various entities. His expertise is expected to enhance Algernon's drug repurposing initiatives. CEO Christopher Moreau expressed confidence in Bloomfield's ability to contribute positively to the company's strategic goals.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced successful results from its preclinical study on AP-188 (DMT), showing a 40% increase in cortical neuron growth with statistical significance using a sub-hallucinogenic dose. Conducted by Charles River Laboratories, the study aims to explore DMT's neuroplastic effects for stroke treatment with minimal side effects. The next phase involves analyzing treatment duration from 1 to 72 hours, with results expected by October 2021. Algernon aims to lead human trials for DMT targeting ischemic stroke.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced the initiation of an NP-120 (Ifenprodil) research program for small cell lung cancer (SCLC) and appointed Dr. William North as lead consultant. Ifenprodil, shown to inhibit tumor growth in previous studies, was tested in combination with chemotherapy and demonstrated significant additive effects. The company signed a licensing agreement with Dartmouth College for a method of use patent related to neuroendocrine cancers and plans to submit a pre-IND meeting request to the FDA for SCLC clinical program guidance.
Algernon Pharmaceuticals has signed an exclusive licensing agreement with Dartmouth College for a method of use patent targeting neuroendocrine cancers that express functional NMDA receptors. The licensing deal includes a fee structure and ongoing royalties on sales. Algernon aims to leverage Ifenprodil, which has shown significant anti-tumor effects in pancreatic cancer models, to progress into clinical trials. The company plans to submit a pre-IND meeting request to the FDA for guidance on its clinical program design, emphasizing its commitment to advancing cancer treatment.
Algernon Pharmaceuticals Inc. (OTCB: AGNPF) has achieved 70% enrollment in its Phase 2 clinical trial of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough. The trial, involving 20 patients, aims to assess Ifenprodil's effectiveness in preserving lung function and reducing chronic cough frequency over 12 weeks. With approximately CAD$3.2M in cash and a CAD$2M refundable tax credit expected, Algernon is positioned for continued development in its drug repurposing strategy.